secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001493152-24-011402
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem posts $18.2M Phexxi net sales in 2023; operating loss improves 79% YoY; Aditxt acquisition pending
--------------------------------------------------------------------------------

- Net product sales $18.2M, up from $16.8M in 2022; Q4 sales $4.8M vs $0.2M.
- Total operating expenses reduced 64% to $36.1M from $101.0M; selling and marketing down 73%.
- Loss from operations improved to $17.8M from $84.1M (79% improvement).
- Entered definitive agreement to be acquired by Aditxt (ADTX); expected closing H2 2024.
- Cash: $0.6M restricted at Dec 2023; compared to $2.8M unrestricted at Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/0001493152-24-011402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224011402/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer